All Pfizer published press releases by date and/or category of news
02.16.2023 Medicines Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study 02.16.2023 Medicines Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults 02.10.2023 Medicines FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Media Asset Library
A collection of assets for use by media.
The latest news from Pfizer and its strategic partners
04.26.2022 Partnerships Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate 02.14.2022 Partnerships Pfizer joins the Open Targets consortium
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
United States, Canada and Latin America
Europe, the Middle East and Africa
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.